While preliminary, and requiring validation in further studies, these results suggest that quantifying CCR5 signal on circulating TACs may identify patients who might respond to anti-CCR5 therapy, thus minimizing cancer spread and improving patient survival. This evidence concerns the gene CCR5 and cancer.